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Abstract 
Background: To reduce the number of patients with depression, biomarkers for clarifying psychiatric disorders 
are warranted. Numerous candidates have been proposed; however, near-infrared spectroscopy (NIRS) with multi-
channel probes and a dexamethasone/corticotropin-releasing hormone (DEX/CRH) test are still surviving for practical 
demand. Thirty-one outpatients with depressed moods were analyzed using both biological tests.
Results: The non-suppressors, as indicated by the DEX/CRH test, exhibited a high severity on the Hamilton Depres-
sion Scale and severe anxiety on the State Trait Anxiety Scale. In addition, a unique response was identified via NIRS in 
the same group suggested by the DEX/CRH assessment.
Conclusions: The results obtained from these biological tests did not fit well with the category defined by operative 
diagnostic criteria, such as the Diagnostic and Statistical Manual of Mental Disorders or The International Classification 
of Diseases. Thus, it is critical that the utility evaluations of candidate biomarkers not be assessed by comparisons with 
the categorized criteria for a specific psychiatric disorder.
Trial registration UMIN000013214, Registered 21 February 2014
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Background
A depressed mental state is caused by non-specific 
mental disorders, such as a mood disorder, schizophre-
nia, substance abuse, a personality disorder, or nearly 
every psychiatric condition. If it is more prolonged than 
expected, several types of costs related to individuals 
with depressed moods will increase. A recent analysis 
indicated a 21.5 % cost increment, $173.2 billion (2005) 
to $210.5 billion (2010), within 5 years, and this cost will 
be further increased [9]. Another analysis with regard 
to the global DALY (disability-adjusted life year) indi-
cated that the cost associated with depression would 
represent the primary cost of all disorders, including 
physical disorders, in 2030, and it ranked 3rd in 2004 
(http://www.who.int/healthinfo/global_burden_disease/
GBD_report_2004update_part4.pdf ). These analyses 
have provided warnings regarding the importance of 
depression prevention. In addition, to perform effective 
treatment, a precise assessment based on scientific data 
comprises a key factor.
Evidence regarding the relationship between depres-
sion severity and blood flow measurements scaled by 
Near-Infrared Spectroscopy (NIRS) is accumulating [30, 
36, 41]. NIRS comprises a non-invasive imaging device 
that uses multiple channels to visualize brain activity. It 
has been developed as a result of the demand to consider 
a differential diagnosis in patients with depressed moods 
despite the administration of antidepressant agents for an 
extended period. A reliable biological marker is required 
to identify a specific psychiatric disorder because diag-
nosis in psychiatry currently relies on expressed symp-
toms or spoken words. NIRS comprises a device that 
applies knowledge of neuroscience through the assess-
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potential candidate for a reliable biomarker depends on 
an endocrine imbalance. Particularly in the assessment 
of disturbed regulation of the hypothalamic-pituitary-
adrenocortical (HPA) system, dexamethasone/corticotro-
pin-releasing hormone (DEX/CRH) has been extensively 
investigated with a view towards the differential diagnosis 
of depression prior to the development of NIRS. Origi-
nally, the dexamethasone suppression test (DST) was 
used to diagnosis Cushing’s syndrome [22]; this endocrine 
reaction has also been implemented for the diagnosis of 
endogenous depression. The current standard method is 
a DEX/CRH test in combination with the administration 
of CRH, which has been reported to increase the sensitiv-
ity from 60 to 80 % for the classic type of depression [12, 
13]. There is an unavoidable burden regarding the applica-
tion of this method for practical usage; however, these two 
biological methods have been considerably implemented 
in previous decades for investigating the biomarkers of 
depression.
In the current study, we investigated patients with a 
depressed mental state. Following a diagnosis according 
to the DSM-IV or psychological assessments, two tests 
using both endocrine (DEX/CRH) and neuroimaging 
(NIRS) assessments were applied. The aim of the current 
work was to identify the relationship between the psychi-
atric diagnosis based on the expressed symptoms and the 
assessment of two biomarkers.
Methods
Subjects
The subjects comprised 31 outpatients (15 men and 
16 women; mean age: 44.2 years, SD: 12.2 years) with a 
depressive state, who were recruited from patients who 
attended the Neuropsychiatry Department of Osaka 
Medical College. The demographic details of the psychi-
atric diagnoses are shown in Table  1. We have adopted 
structured clinical interview for DSM-IV TR (SCID) for 
clinical assessment [7].
The severity of the index depressive episode was 
assessed with the 21-item version of the Hamilton 
depression rating scale (HAMD) [10, 15], on the admis-
sion day (DEX/CRH on the 2nd day and NIRS on the 3rd 
day). Enrolled patients (n = 31) were not strictly limited 
along with the HAMD score because all of the partici-
pants had the difficulty to live their life. Regarding the 
self-evaluation tool for anxiety, the STAI, the State-Trait 
Anxiety Inventory [26, 34], was administered to the par-
ticipants on admission day. The majority of the patients 
were medicated with antidepressants; however, we did 
not control for the class of antidepressant medication. In 
addition, we assessed the psychiatric disorders of patients 
along with the SCID method; therefore, psychiatric 
comorbidities were not controlled.
DEX/CRH test
The DEX/CRH test was conducted according to the 
method described by Zobel et al. [42]. The subjects were 
pretreated with an oral dose of 1.5 mg of DEX at 2200 h 
on the 1st admission day. On the next day, a vein was 
cannulated at 1400 h to collect blood at 1430, 1500, 1530, 
1545, and 1600  h via an intravenous catheter. Human 
CRH (100 μg) was intravenously administered at 1400 h 
immediately after the initial blood collection. The plasma 
concentrations of ACTH and cortisol were measured via 
radioimmunoassay at SRL Corporation (Tokyo, Japan). 
The detection limits for ACTH and cortisol were 5.0 pg/
ml and 1.0 μg/dl, respectively.
The definition of the subtypes of the cortisol sup-
pression pattern followed previously described criteria 
[19, 14] and included incomplete-suppressors (DEX/
CRH-cortisol  ≥5  μg/dl, moderate-suppressors (1  μg/
dl  ≤  DEX/CRH-cortisol  <5  μg/dl), and enhanced-sup-
pressors (DEX/CRH-cortisol <1 μg/dl). We also included 
a non-suppressor group with cortisol >5 μg/dl at the test 
onset to reduce the number of incomplete suppressors 
(onset-cortisol <5 μg/dl).
NIRS measurement
The NIRS measurements were performed using a 
22-channel ETG-4000 Optical Topography System 
(Hitachi Medical Corporation, Tokyo, Japan). This 
machine used two sets of wavelengths of near-infrared 
light (695 and 830  nm, respectively) to identify differ-
ences in the absorption spectrum, which thus enabled 
the measurement of oxy-Hb and deoxy-Hb [23]. Sev-
enteen emitter probes and 16 detector probes were 
plugged into a 3 ×  11 array. The distance between the 
pair of emission and detector probes was 3.0  cm; the 
measuring area between each pair of detector probes 
was defined as a “channel.” Probes were placed on the 
frontal region of the participant. The lowest probes 
were positioned along the Fp1–Fp2 line in accord-
ance with the international 10–20  system used in 
electroencephalography.
Activation task
Changes in the hemoglobin concentration were meas-
ured during the verbal fluency task [37]. The cognitive 
activation task was structured to include a 30-s pre-
task period, a 60-s task period, and a 70-s post-task 
period. For the pre- and post-task baseline periods, the 
participants were instructed to consecutively repeat 
five Japanese vowels (a, i, u, e, o) aloud. During the 
task periods, they were instructed to generate as many 
Japanese words as possible that began with a desig-
nated syllable. The initial syllables were presented in 
counterbalanced order among the participants with 
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each syllable changing every 20  s (0–20  s: /to/, /na/, 
/a/; 20–40 s:/se/, /i/, /ki/; 40–60 s: /o/, /ta/, /ha/) dur-
ing the 60-s task period.
Measurement environment
Each participant was seated in a comfortable chair and 
instructed to remain still to prevent movement artifacts; 
specifically, head movements, strong biting, or unneces-
sary eyebrow movements were minimized during the 
NIRS measurements. The data that clearly contained 
motion artifacts, based on both our observations and 
NIRS recordings, were excluded from further analyses.
Statistical analysis
All statistical analyses were performed with JMP Pro® 
software (Ver. 11.0, SAS Institute Japan Ltd., Tokyo, 
Japan). Intergroup comparisons were conducted for 
HAMD, STAI scores and the gained scores from NIRS 
instrument according to the Kruskal–Wallis test. A value 
of p < 0.05 was considered statistically significant.
Results
According to the previously described criteria for the 
division of the DEX/CRH response, the numbers of par-
ticipants in the four groups divided by the cortisol reac-
tion are indicated in Table 2.
First, the association between the reaction in the DEX/
CRH test and the severity of depression determined by 
the HAMD assessment was investigated. The HAMD 
was recorded by another clinician in a blind manner. 
There was a difference in the mean value of the HAMD 
score between the non-suppressors and the other two 
main groups, incomplete suppressors and moderate sup-
pressors (Fig. 1 Kruskal–Wallis analysis Chi square 7.37, 
p  =  0.06). Second, the STAI, which is a self-evaluation 
tool for anxiety, significantly represented the character-
istic psychological feature of the non-suppressor group 
compared with the other three groups (Fig.  2 Kruskal–
Wallis analysis Chi square 7.58, p = 0.06). Moreover, we 
compared the results of the NIRS assessment with the 
reaction of the DEX/CRH test. Similar to the HAMD 
assessment, the NIRS recording was performed by a 
lab technician in a blind manner. The results indicated 
that the values of the center of gravity at the frontal 
lobe in the non-suppressor group, which comprised the 
representative values in NIRS, were significantly differ-
ent compared with the other three groups by post hoc 
analysis (Fig. 3 Kruskal–Wallis analysis Chi square 7.02, 
p  =  0.07). No significant age difference between the 
groups that were defined by the two biological methods 
was found (data not shown).
Discussion
The current sample size is relatively small to provide a 
definitive conclusion; however, our current work has an 
advantage in which we employed cases regardless of the 
diagnosis of psychiatric disorders. Therefore, there is the 
potential that the novel scientific findings identified from 
our sample are consistent across diagnoses based on the 
operative diagnostic criteria, such as the DSM. In addi-
tion, this is the first report to assess confirmed cases with 
depressed mood by two representative assessment meth-
ods for depression.
Regarding the DEX/CRH test, it has been reported 
that 60–80  % of patients with depression exhibited an 
Table 2 Number of patients with depression divided by the DEX/CRH test (n = 31)
DEX/CRH-cortisol Onset cortisol Male Female Total
Enhanced-suppressors <1 μg/dl 2 5 7
Moderate-suppressors 1 μg/dl ≤ <5 μg/dl 2 8 10
Incomplete-suppressors ≥5 μg/dl Onset cortisol <5 μg/dl 8 3 11
Non-suppressors ≥5 μg/dl Onset cortisol ≥5 μg/dl 3 0 3
Fig. 1 Diamond plot of the HAMD 21 assessment and DEX–CRH 
test (n = 31). Kruskal–Wallis analysis Chi square 7.37, p = 0.06. Post 
hoc analysis non-suppressors, 26.3 ± 3.2, vs incomplete suppressors, 
13.7 ± 8.2, p = 0.04, vs moderate suppressors, 14.8 ± 5.8, p = 0.03
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increased cortisol response prior to the initiation of treat-
ment [18, 42]. It is partly because all participants in this 
study received medical treatment prior to the assessment, 
whereas only 11 % (3/31) of the participants in this study 
exhibited an increase cortisol response (non-suppressors). 
Moreover, most previous studies utilizing DEX/CRH test 
have been based on data obtained from inpatients [18, 
20], which implies a clinical subgroup with severe symp-
toms, whereas our current sample consisted of a depres-
sion severity at the outpatient level. Moreover, the group 
that enrolled the largest sample size did not include data 
for individuals with a HAMD less than 15 [18], whereas 
the average HAMD score was 15.6 ±  7.5 in our sample. 
This difference has a significant impact on the interpreta-
tion of our data. The percentage of non-suppressors was 
not high because of the enrolled mild subtype of depres-
sion; however, every non-suppressor patient exhibited 
a high score on the HAMD assessment (average score 
of HAMD: 27.8) despite inconsistencies in the psychiat-
ric disorders across three patients (two patients: 296.23 
major depressive disorder, and one patient: 300.3 obses-
sive compulsive disorder). Thus, the DEX/CRH approach 
should again be considered a potentially useful biomarker 
for dividing the subclasses of depression.
With regard to psychological aspects assessed by STAI, 
the Kruskal–Wallis analysis indicated there was no sig-
nificant difference for the divided subgroups regard-
ing the DEX/CRH test; however, a trend was identified 
particularly for the non-suppressor group (Chi square 
7.58, p = 0.06). Anxiety is a non-specific feature of psy-
chiatric disorders. Therefore, the severity of anxiety is 
not fundamentally considered to be scaled by a bio-
logical method. Although the scale is simply based on a 
self-evaluation scale, our results indicated the potential 
finding that anxiety across psychiatric disorders, includ-
ing depression, is represented by a biological scale, such 
as DEX/CRH. Anxiety-related stimuli cause a systemic 
response through neural circuits centered on the amyg-
dala, which enhances the increment of cortisol [38]. 
Therefore, an association between the altered DEX/CRH 
result and the anxiety scale is reasonable. A previous 
study demonstrated that individuals with depression and 
comorbid anxiety (n  =  18) related disorders exhibited 
a significantly lower cortisol level compared with pure 
depression patients (n  =  36) [40]. The non-suppressor 
group, which showed higher anxiety, more severe depres-
sive symptoms and a distinguished response in the DEX/
CRH, should be regarded as one entity in terms of dif-
ferent biological and psychological reactions. Thus, larger 
Fig. 2 Diamond plot of the STAI assessment and DEX–CRH test 
(n = 31). Kruskal–Wallis analysis Chi square 7.58, p = 0.06. Post hoc 
analysis non-suppressors, 140 ± 4.0, vs incomplete suppressors, 
107 ± 18.8, p = 0.03, vs moderate suppressors, 103 ± 18.1, p = 0.01, 
vs enhanced suppressors, 109 ± 24.6, p = 0.04
Fig. 3 Diamond plot of the NIRS assessment (value of the center of 
gravity at the frontal lobe) and DEX–CRH test (n = 31). Kruskal–Wallis 
analysis Chi square 7.02, p = 0.07. Post hoc analysis non-suppressors, 
82.0 ± 9.6, vs incomplete suppressors, 58.0 ± 11.4, p = 0.02, vs mod-
erate suppressors, 55.5 ± 12.8, p = 0.02, vs enhanced suppressors, 
56.9 ± 13.2, p = 0.04
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sample sizes, especially for the non-suppressor group, 
are necessary to clarify the association between the STAI 
scale and DEX/CRH results.
Accumulating evidence supports the relationship 
between NIRS and the diagnosis of psychiatric disor-
ders [21, 24, 36]. Thus, NIRS is one of the most attractive 
tools for adopting a biological assessment for clinical 
practice. One reason is that the device requires only 
10–15 min for each individual if VFT is adopted for the 
assessment. NIRS is sufficiently easy to adopt, even for 
adolescents, for the evaluation of psychiatric disorders, 
such as depression, bipolar disorder, and schizophre-
nia. General interpretation on VFT is a neurocognitive 
battery for assessing verbal ability or executive control 
ability. This battery is widely used for assessing these 
abilities of patients after stroke, patients with Alzhei-
mer’s disease or Parkinson’s disease [33]. In the current 
study, we have utilized this battery mainly for record-
ing the measurements of oxy-Hb in the brain, therefore 
the task performance (the number of words) on each 
individual were not recorded. The comparison of the 
performance on VFT between each groups will be of 
interest. Future work should focus on the task perfor-
mance across various psychiatric disorders. One of the 
critical issues regarding the NIRS device is that insuffi-
cient data are obtained from the perspective of neurosci-
ence. In an analysis of a larger sample than the current 
work, our group recently demonstrated that the sever-
ity of depression scaled by the HAMD was negatively 
associated with the integral value of the blood flow at 
the frontal lobe (n = 43) [16]. This finding was charac-
terized by the point that the assessment was not limited 
to depressed patients who satisfied the criteria defined 
by the DSM or ICD. Moreover, several biomarkers, such 
as DEX/CRH, NIRS and other factors, cannot guarantee 
the specificity of psychiatric disorders defined by opera-
tional diagnostic criteria. The current findings indicated 
that individuals with a Non-Suppression reaction in the 
DEX/CRH test exhibited a fairly increased value of the 
center of gravity at the frontal lobe. A general interpre-
tation regarding the increased value of the center of 
gravity implies the existence of bipolarity [36]. In spe-
cific areas such as the left inferior frontal lobe, [oxy-Hb] 
was decreased in patients with panic disorders [27, 28]. 
Although the current work did not focus on a specific 
channel of NIRS, future research should analyze the 
data for a specific channel by assessing a larger sample 
series. Thus, a larger sample size is critical to validate the 
current work to determine the unknown mechanism of 
endocrine imbalance and brain response. In addition, 
the biological data from the mentally healthy controls 
will serve as a useful reference, although the current 
design has not been adopted to collect them. Moreover, 
the length of the duration of mental illness has a possible 
effect on the result from the biological assessment. This 
should be considered in future studies.
Biological assessments embedded in the diagnosis of 
specific psychiatric disorders are proceeding. Candidate 
methods have been evaluated using the concordance rate 
for diagnosis defined by the operative criteria to date; 
however, a universally accepted biomarker has not been 
identified. Despite substantial efforts to identify a bio-
logical marker, the methodological approach for objec-
tive evaluation is incorrect in terms of the fact that the 
concordance rate between biological assessments and 
psychiatric diagnoses based on the artificial operative 
system is not sufficient to satisfy practical demands. For 
example, a genetic approach has indicated considerable 
overlap between schizophrenia and bipolar disorder [6, 
29]; therefore, the current understanding regarding these 
disorders has been modified to indicate that the two dis-
orders are related diseases in terms of the genetic aspects 
[31]. Moreover, recent reports have indicated consider-
able genetic overlap across several types of psychiatric 
disorders [4, 8, 11, 25]. According to a recent perspective 
based on genetic analyses, Craddock and his group have 
advocated the theory that psychiatric disorders are con-
sidered a spectrum [3]. It is true that a decreased frontal 
lobe is present in the brains of individuals with schizo-
phrenia and bipolar disorder, as well as depression [5, 
35]. Regarding therapeutic agents, antidepressants are 
effective for the improvement of symptoms in schizo-
phrenia and bipolar disorders [32, 39]. Alternatively, 
antipsychotic agents are used for the treatment of depres-
sion [2]. Based on the traditional diagnostic category, it is 
impossible to explain the differences between psychiat-
ric disorders by genetic or morphological factors or the 
responsiveness to therapeutic drugs. Our current finding 
indicates a trend of correlation between the severity of 
depression and the response to the DEX/CRH test; how-
ever, the diagnostic categories did not sufficiently fit the 
biological assessment. Moreover, our findings also sug-
gest that the current diagnostic criteria are not valid for 
the assessment of biological markers in psychiatric disor-
ders. Thus, the diagnostic criteria must be updated based 
on the contributions of biological assessments, such as 
DEX/CRH or NIRS [1, 17].
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